08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

CP024: Phase I data

Critical Pharmaceuticals reported data from a Phase I trial in 7 healthy volunteers showing that 2-6 mg doses of intranasal CP024 plus an infusion of octreotide "strongly" induced the production of insulin-like growth factor-1 (...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Clinical News

CP024: Interim Phase I data

Interim data from a Phase I trial in healthy volunteers showed that intranasal CP024 produced insulin-like growth factor-1 (IGF-I) levels comparable to that of a subcutaneous injection of an undisclosed marketed hGH product. CP024 was...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Clinical News

Critical Pharmaceuticals preclinical data

In rats, repeated intranasal administration of CP024 over 14 days was tolerable with no adverse effects reported. The company plans to start Phase I testing of the human growth hormone (hGH) formulated with its CriticalSorb...